Success Metrics

Clinical Success Rate

100.0%

Based on 4 completed trials

Completion Rate

100%(4/4)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_2

20%

Ph phase_3

80%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 2Efficacy & side effects

1(20.0%)

Phase 3Large-scale testing

4(80.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(4)

Other(1)

Detailed Status

Completed4

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 21 (20.0%)

Phase 34 (80.0%)

Trials by Status

completed480%

unknown120%

Recent Activity

0 active trials

Showing 5 of 5

completedphase_2

Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin Plus Vincristine in the Treatment of Kaposi's Sarcoma in Patients With AIDS

NCT00001059

unknownphase_3

A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma

NCT00002318

completedphase_3

Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma.

NCT00002147

completedphase_3

Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma

NCT00002105

completedphase_3

A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma

NCT00002319

Clinical Trials (5)

Showing 5 of 5 trials

NCT00001059Phase 2

Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin Plus Vincristine in the Treatment of Kaposi's Sarcoma in Patients With AIDS

Completed

NCT00002318Phase 3

A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma

Unknown

NCT00002147Phase 3

Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma.

Completed

NCT00002105Phase 3

Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma

Completed

NCT00002319Phase 3

A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5